Search

This study introduces a novel tyrosinase-based biosensor designed to simultaneously detect tyrosinase, tyrosine, L-DOPA, and L-DOPA quinone. The biosensor, designated as GCE/GNP/Cys/Chit/Tyrase, was developed by immobilizing tyrosinase on a modified glassy carbon electrode (GCE) that incorporates electrodeposited gold nanoparticles, cysteine, and chitosan. The morphology of the biosensor was characterized using scanning electron microscopy (SEM). The electrochemical behaviors of the biosensor were explored in response to the target analytes. Key analytical characteristics were assessed, including linear range, sensitivity, selectivity, limits of detection and quantification, long-term stability, repeatability, reproducibility, electrochemically active surface area, and charge transfer behavior. The biosensor demonstrated a linear response range of 1–120 μM, with an impressive sensitivity of 200.4 mA.Lmol−1cm−2 and a detection limit of 27 μM. This study provides a comprehensive evaluation of the analytical features of tyrosinase-based biosensors. Additionally, the biosensor was applied to quantify dopamine in brain tissue, utilizing a calibration curve derived from the fabricated biosensor. The dopamine concentration measured in five Wistar rats was 35 ± 2.75 μM, reflecting the mean and standard deviation, respectively. These results confirm the biosensor's capability for accurately detecting this critical neurotransmitter in the brains of Wistar rats. This investigation underscores the potential of tyrosinase-based biosensors for diverse analytical applications in biological samples.

Although there is general consensus that altered brain structure and function underpins addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-informed approaches into their practice. We recently launched the Neuroscience Interest Group within the International Society of Addiction Medicine (ISAM-NIG) to promote initiatives to bridge this gap. This article summarizes the ISAM-NIG key priorities and strategies to achieve implementation of addiction neuroscience knowledge and tools for the assessment and treatment of substance use disorders. We cover two assessment areas: cognitive assessment and neuroimaging, and two interventional areas: cognitive training/remediation and neuromodulation, where we identify key challenges and proposed solutions. We reason that incorporating cognitive assessment into clinical settings requires the identification of constructs that predict meaningful clinical outcomes. Other requirements are the development of measures that are easily-administered, reliable, and ecologically-valid. Translation of neuroimaging techniques requires the development of diagnostic and prognostic biomarkers and testing the cost-effectiveness of these biomarkers in individualized prediction algorithms for relapse prevention and treatment selection. Integration of cognitive assessments with neuroimaging can provide multilevel targets including neural, cognitive, and behavioral outcomes for neuroscience-informed interventions. Application of neuroscience-informed interventions including cognitive training/remediation and neuromodulation requires clear pathways to design treatments based on multilevel targets, additional evidence from randomized trials and subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to address these challenges by promoting international collaboration between researchers and clinicians, developing harmonized protocols and data management systems, and prioritizing multi-site research that focuses on improving clinical outcomes.